Given the aggressiveness of AML, limited therapeutic options, and our serendipitous finding of BCOR-mutant sensitivity to DHODH inhibition, we tested whether BCOR mutations establish a synthetic lethal interaction with DHODH blockade. Here, BCOR is linked to acute myeloid leukemia.